2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial (Unknown)
Free access
- New search for: Lehtonen, Miikka
- New search for: Sormunen, Jorma
- New search for: Luukkaala, Tiina
- New search for: Marttila, Timo
- New search for: McDermott, Ray
- New search for: Joensuu, Timo
- New search for: Lehtinen, Ilari
- New search for: Ginman, Claes
- New search for: Kellokumpu-Lehtinen, Pirkko-Liisa
- New search for: Lehtonen, Miikka
- New search for: Sormunen, Jorma
- New search for: Luukkaala, Tiina
- New search for: Marttila, Timo
- New search for: McDermott, Ray
- New search for: Joensuu, Timo
- New search for: Lehtinen, Ilari
- New search for: Ginman, Claes
- New search for: Kellokumpu-Lehtinen, Pirkko-Liisa
In:
Acta Oncologica
;
61
, 8
;
963-971
;
2022
- Article (Journal) / Electronic Resource
-
Title:2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial
-
Contributors:Lehtonen, Miikka ( author ) / Sormunen, Jorma ( author ) / Luukkaala, Tiina ( author ) / Marttila, Timo ( author ) / McDermott, Ray ( author ) / Joensuu, Timo ( author ) / Lehtinen, Ilari ( author ) / Ginman, Claes ( author ) / Kellokumpu-Lehtinen, Pirkko-Liisa ( author )
-
Published in:Acta Oncologica ; 61, 8 ; 963-971
-
Publisher:
- New search for: Taylor & Francis
-
Publication date:2022-08-03
-
Size:9 pages
-
ISSN:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:Unknown
-
Keywords:
-
Source:
Table of contents – Volume 61, Issue 8
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 907
-
Cancer in the Faroe Islands from 1960-2019 – incidence, mortality, and comparisons with the other Nordic countriesKristiansen, Marnar F. / Mikkelsen, Ronja M. / Kristiansdóttir, Tordis / Rasmussen, Páll / Andórsdóttir, Guðrið / Hansen, Sæunn Ó. / Nielsen, Kári R. / á Steig, Bjarni / Strøm, Marin / Petersen, Maria Skaalum et al. | 2022
- 922
-
Beta-blocker use and urothelial bladder cancer survival: a Swedish register-based cohort studyUdumyan, Ruzan / Botteri, Edoardo / Jerlstrom, Tomas / Montgomery, Scott / Smedby, Karin E. / Fall, Katja et al. | 2022
- 955
-
Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer – the MetAction precision medicine studyRee, Anne Hansen / Mælandsmo, Gunhild M. / Flatmark, Kjersti / Russnes, Hege G. / Gómez Castañeda, Mónica / Aas, Eline et al. | 2022
- 963
-
2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trialLehtonen, Miikka / Sormunen, Jorma / Luukkaala, Tiina / Marttila, Timo / McDermott, Ray / Joensuu, Timo / Lehtinen, Ilari / Ginman, Claes / Kellokumpu-Lehtinen, Pirkko-Liisa et al. | 2022
- 1004
-
Dosimetric effects of respiratory motion during stereotactic body radiation therapy of lung tumorsSarudis, Sebastian / Karlsson, Anna / Nyman, Jan / Bäck, Anna et al. | 2022
- 1019
-
Bladder-sparing (chemo)radiotherapy in elderly patients with muscle-invasive bladder cancer: a retrospective cohort studyVerschoor, Noortje / Heemsbergen, Wilma D. / Boormans, Joost L. / Franckena, Martine et al. | 2022